A5031786797- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Pharmacogenetics and Drug Metabolism
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cancer survivorship and care
- Autoimmune and Inflammatory Disorders
- COVID-19 and healthcare impacts
- Chemotherapy-induced cardiotoxicity and mitigation
- Biological Activity of Diterpenoids and Biflavonoids
- Pathogenesis and Treatment of Hiccups
- CNS Lymphoma Diagnosis and Treatment
- Natural product bioactivities and synthesis
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- Inflammatory mediators and NSAID effects
- MicroRNA in disease regulation
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
Instituto de Investigación Biosanitaria de Granada
2016-2025
Universidad de Granada
2017-2025
GEICAM – Spanish Breast Cancer Group
2017-2019
Hospital General Universitario Gregorio Marañón
2019
Centro de Investigación Biomédica en Red de Cáncer
2019
Complejo Hospitalario Universitario de Granada
2007-2018
Hospital Clínico Universitario de Valencia
2006-2014
Abstract Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary tissues from patients. Intrinsic subtype was identified using a PAM50 classifier χ2 tests determined the differences variable distribution. The rate conversion 0% basal-like tumors, 23.1% HER2-enriched (HER2-E) 30.0% luminal B 55.3% A tumors. 40.2% cases, tumors converted...
The prognosis of old or immunocompromised patients with refractory relapsing diffuse large-cell lymphoma (DLCL) is very poor as the current standard salvage therapy autologous stem cell transplantation (ASCT) not feasible for most them. New active regimens an acceptable toxicity profile are needed. We aim to report results a phase II trial GEMOX-R regimen in DLCL.A total 32 received 2-wk intervals if every 3 wk planned six eight courses.Median age population was 69 yr. Forty-one percent were...
To evaluate the effects of an 8-week water physical therapy program on cervical and shoulder pain, pressure sensitivity, presence trigger points (TrPs) in breast cancer survivors.Randomized, controlled trial.To date, no study has investigated cancer.Sixty-six survivors were randomly assigned into two groups: WATER group, who received a exercise or CONTROL group usual care treatment for cancer.The consisted 24 sessions (3 times/week over 8 weeks) low-intensity exercises warm pool (32°C). Each...
Abstract Advanced breast cancer represents a challenge for patients and physicians due its dynamic genomic changes yielding to resistance treatments. The main goal is improve quality of live survival the through most appropriate subsequent therapies based on knowledge natural history disease. In these guidelines, we summarize current evidence available medical management advanced cancer.
The objective of this study was to determine the conversion rate human epidermal growth factor receptor 2 (HER2), estrogen (ER) and progesterone (PR) between primary tumors metastatic lesions in advanced breast cancer. Patients with suspected diagnosis locally recurrent or cancer, either at first relapse after successive disease progressions, who had an appropriately preserved sample from a tumor were scheduled for biopsy lesion, included. Blinded determinations status on paired samples...
BackgroundCYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main active metabolite, endoxifen. Poor CYP2D6 metabolizers (PM) have lower endoxifen plasma concentrations and possibly benefit less from treatment with tamoxifen. We evaluated dose adjustment PM patients order to obtain of comparable extensive metabolism (EM).Patients methodsComprehensive genotyping metabolite were performed among 249 breast cancer adjuvant Tamoxifen was increased 40 mg 60 daily for 4-month...
Breast cancer (BC) is the most common cause of leptomeningeal disease (LMD) and second brain metastases (BMs) among all solid malignancies. Both BMs LMD are associated with high morbidity mortality treatment options limited. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate combining a HER2-targeting topoisomerase I inhibitor, has shown activity in HER2-positive (HER2[+]) HER2-low tumors both preclinical clinical settings. Similarly, T-DXd efficacy HER2[+] BC patients central...
Mantle cell lymphoma constitutes one of the lymphomas with poorest prognosis at relapse limited effective salvage regimens due to advanced age. We present results a new regimen, rituximab, gemcitabine and oxaliplatin (GEMOX-R), in 14 patients relapsing (n = 9) or refractory 5) mantle lymphoma. The median number cycles was 5.5 for total 72 evaluated current study. age 69.5 years high-risk features. Patients received mean prior treatment lines 1.79. Sixty-four percent achieved CR (total...
Background Estrogen receptor-positive breast cancer tumors depend on estrogen signaling for their growth and replication can be treated by anti-estrogen therapy with tamoxifen.Polymorphisms of the CYP2D6 CYP2C19 genes are associated an impaired response to tamoxifen.The study objective was investigate impact genetic polymorphisms in pharmacokinetics tamoxifen its metabolites Spanish women who were candidates therapy.Methods: We studied 90 cancer, using Am-pliChip CYP450 test determine gene...
Objectives Opioid-induced constipation (OIC) can affect up to 63% of all patients with cancer. The objectives this study were assess quality life as well efficacy and safety naloxegol, in cancer OIC. Methods An observational was made a cohort OIC exhibiting an inadequate response laxatives treated naloxegol. sample consisted adult outpatients Karnofsky performance status score ≥50. Patient Assessment Constipation Quality Life Questionnaire (PAC-QOL) the Symptoms (PAC-SYM) applied for 3...
BackgroundTrastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity the most important side effect of trastuzumab treatment, cardiac monitoring should be priority. The purpose this study evaluate plasma NT-proBNP level and major cardiovascular risk factors as possible early predictors trastuzumab-induced patients.MethodsWe conducted retrospective observational involving 66 patients with treated trastuzumab. Left ventricle ejection...
Tamoxifen is a drug used for hormone receptor-positive breast cancers, primarily metabolised by the CYP2D6 enzyme into active metabolites such as endoxifen. displays varying degrees of activity depending on its genotype. This study aims to analyse effect an early increase in tamoxifen dose poor metabolisers (PM) survival.We enrolled 220 patients diagnosed with cancer who were treated tamoxifen. polymorphisms determined, and phenotype was estimated according Clinical Pharmacogenetics...
Taiwaniaquinoids are a unique family of diterpenoids predominantly isolated from Taiwania cryptomerioides Hayata. Previously, we evaluated the antiproliferative effect several synthetic taiwaniaquinoids against human lung (A-549), colon (T-84), and breast (MCF-7) tumor cell lines. Herein, report in vitro vivo antitumor activity most potent compounds. Their cytotoxic healthy peripheral blood mononuclear cells (PBMCs) has also been examined. We underscore limited toxicity compound C36 PBMCs...